VapE Antibody (G-9): sc-390036
- VapE Antibody (G-9) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 1-206 representing full length virulence associated protein virulence associated protein VapE of Rhodococcus equi origin
- VapE Antibody (G-9) is recommended for detection of virulence associated protein VapE of Rhodococcus equi origin by WB, IP, IF and ELISA
- Anti-VapE Antibody (G-9) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for VapE Antibody (G-9). This work is in progress.
QUICK LINKS
VapE Antibody (G-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects virulence associated protein VapE of Rhodococcus equi origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VapE (G-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VapE, consisting of 206 amino acids, is encoded by the virulence plasmid pREAT701 (p33701) of R. equi, a gram-positive bacterium known to cause pyogranulomatous pneumonia in foals and pose significant risks to immunocompromised humans. Understanding VapE′s structure is crucial, as VapE plays a vital role in the bacterium′s ability to evade the host immune response, thereby contributing to the severity of infections. VapE′s unique structural features allow interaction with host cell mechanisms, facilitating the establishment of infection and making VapE a key target for therapeutic interventions. R. equi infections are particularly concerning, as these infections are the leading cause of foal mortality within the first six months of life, highlighting the importance of studying proteins like VapE to develop effective treatments and preventive measures.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
VapE Antibody (G-9) References:
- DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC 33701 and 103. | Takai, S., et al. 2000. Infect Immun. 68: 6840-7. PMID: 11083803
- Immunoglobulin G subisotype responses of pneumonic and healthy, exposed foals and adult horses to Rhodococcus equi virulence-associated proteins. | Hooper-McGrevy, KE., et al. 2003. Clin Diagn Lab Immunol. 10: 345-51. PMID: 12738629
- Deletion of vapA encoding Virulence Associated Protein A attenuates the intracellular actinomycete Rhodococcus equi. | Jain, S., et al. 2003. Mol Microbiol. 50: 115-28. PMID: 14507368
- Rhodococcus equi secreted antigens are immunogenic and stimulate a type 1 recall response in the lungs of horses immune to R. equi infection. | Kohler, AK., et al. 2003. Infect Immun. 71: 6329-37. PMID: 14573652
- The LysR-type transcriptional regulator VirR is required for expression of the virulence gene vapA of Rhodococcus equi ATCC 33701. | Russell, DA., et al. 2004. J Bacteriol. 186: 5576-84. PMID: 15317761
- VapI, a new member of the Rhodococcus equi Vap family. | Polidori, M. and Haas, A. 2006. Antonie Van Leeuwenhoek. 90: 299-304. PMID: 16871422
- Molecular characterization of Rhodococcus equi from horse-breeding farms by means of multiplex PCR for the vap gene family. | Monego, F., et al. 2009. Curr Microbiol. 58: 399-403. PMID: 19205798
- Development of a live, attenuated, potential vaccine strain of R. equi expressing vapA and the virR operon, and virulence assessment in the mouse. | Whitehead, AE., et al. 2012. Vet Immunol Immunopathol. 145: 479-84. PMID: 22088674
- Development of ELISA test for determination of the level of antibodies against Rhodococcus equi in equine serum and colostrum. | Witkowski, L., et al. 2012. Vet Immunol Immunopathol. 149: 280-5. PMID: 22883938
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VapE Antibody (G-9) | sc-390036 | 200 µg/ml | $316.00 | |||
VapE Antibody (G-9) AC | sc-390036 AC | 500 µg/ml, 25% agarose | $416.00 | |||
VapE Antibody (G-9) HRP | sc-390036 HRP | 200 µg/ml | $316.00 | |||
VapE Antibody (G-9) FITC | sc-390036 FITC | 200 µg/ml | $330.00 | |||
VapE Antibody (G-9) PE | sc-390036 PE | 200 µg/ml | $343.00 | |||
VapE Antibody (G-9) Alexa Fluor® 488 | sc-390036 AF488 | 200 µg/ml | $357.00 | |||
VapE Antibody (G-9) Alexa Fluor® 546 | sc-390036 AF546 | 200 µg/ml | $357.00 | |||
VapE Antibody (G-9) Alexa Fluor® 594 | sc-390036 AF594 | 200 µg/ml | $357.00 | |||
VapE Antibody (G-9) Alexa Fluor® 647 | sc-390036 AF647 | 200 µg/ml | $357.00 | |||
VapE Antibody (G-9) Alexa Fluor® 680 | sc-390036 AF680 | 200 µg/ml | $357.00 | |||
VapE Antibody (G-9) Alexa Fluor® 790 | sc-390036 AF790 | 200 µg/ml | $357.00 |